Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

ABSTRACT:

Introduction

Uterine fibroids (UFs) are the most common benign tumor arising from myometrium of reproductive age women, with significant financial burden estimated in hundreds of billions of dollars. Unfortunately, there are limitations in available long-term treatment options. Thus, there is a large unmet need in the UF space for noninvasive therapeutics.

Areas covered

Authors reviewed the literature available for elagolix; an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) antagonist recently approved by the US Food and Drug Administration (FDA) in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with UFs in premenopausal women.

Expert opinion

The utility of new-gener

SUBMITTER: Ali M 

PROVIDER: S-EPMC8262561 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature